- AU$37.28m
- AU$23.71m
- AU$6.84m
Australia's Syntara loses most in over 8 months on discounted placement
Brief: Syntara Announces A$8M Placement And Share Purchase Plan
Brief: Syntara Requests Continuation Of Trading Halt
Brief: Syntara Seeks Trading Halt
Australia's Syntara rises on FDA's Fast Track approval for cancer drug
Brief: Syntara Says SNT-5505 Awarded U.S. FDA Fast Track Designation
Brief: Syntara Seeks Trading Halt Pending Announcement On Capital Raising Outcome
Brief: Syntara Appoints Tim Luscombe As CFO
Brief: Syntara Says German MDS Group Awarded A$2.5M Grant
Australia's Syntara falls on discounted placement
Brief: Syntara Says To Raise About A$5 Mln Via Two-Tranche Placement At A$0.028 Per Share
Brief: Syntara Seeks Trading Halt
Brief: Pharmaxis Announces Sale Of Mannitol Respiratory Business To Arna Pharma
Australia's Pharmaxis surges on sale of business, board restructure
Brief: Pharmaxis Seeks Trading Halt
Brief: Pharmaxis Posts FY Revenue From Sale Of Goods Of A$5.8 Million
Brief: Pharmaxis Executed A$4.4 Million Loan Facility Agreement
Brief: Pharmaxis Seeks Trading Halt
Brief: Pharmaxis Plans To Commence Trial Of Combination Therapy In 2023